Clinical Trial Update: A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone [Phase 1]

View source ↗

Summary

Phase 1 study evaluating how paliperidone enantiomers are distributed across formulations and comparing the bioavailability of immediate-release versus extended…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA (PALIPERIDONE)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED